Comparative Pharmacology
Head-to-head clinical analysis: FARXIGA versus INVOKAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FARXIGA versus INVOKAMET.
FARXIGA vs INVOKAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose.
INVOKAMET is a combination of canagliflozin, an SGLT2 inhibitor, and metformin, a biguanide. Canagliflozin inhibits sodium-glucose cotransporter 2 in the renal proximal tubules, reducing glucose reabsorption and increasing urinary glucose excretion. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity.
10 mg orally once daily, with or without food.
Oral: Starting dose: 5 mg canagliflozin/500 mg metformin hydrochloride extended-release twice daily; titrate based on efficacy and tolerability, maximum 150 mg/1000 mg twice daily.
None Documented
None Documented
Terminal elimination half-life 12-13 hours; supports once-daily dosing. Steady-state reached in 5 days.
Canagliflozin: 10–13 hours (multiple dosing); Metformin: 6.2 hours (plasma). Accumulation occurs in renal impairment.
Renal (33% as parent, 66% as glucuronide conjugates in urine); fecal (1.5% as parent); biliary (minor).
Canagliflozin (SGLT2 inhibitor): ~33% renal (1% unchanged, ~33% as glucuronide metabolites), ~52% fecal. Metformin (biguanide): 90% renal unchanged via tubular secretion.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor / Biguanide Combination